← Leaderboards
Sarjan Shah
Auritec Pharmaceuticals, Inc.
$2,548,807
Attributed
$5,097,614
Total exposure
2
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2M · FY2022–25$2.5M$1.9M$1.3M$625K$0
'22
'23
'24
'25
Funding mix
By agency
NIH$5,097,614 · 2
By mechanism
R44$5,097,614 · 2
Top collaborators
- Thomas J. Smith5 shared
Most similar at Auritec Pharmaceuticals, Inc.
Same institution · by research overlap
- John A Moss$9,543,203
- Amanda Malone$4,368,893
Others in their field
Other Rising Stars on “Pharmacologic Substance”
- Lauren Miller · Technical Resources International, Inc.$31,120,905
- Michael Difilippantonio · Leidos Biomedical Research, Inc.$22,364,766
- Mehrinfar Mahzad · Fisher Bioservices, Inc.$18,271,500
- Bambra Stokes · Ppd Development Lp$17,155,112
- Xuping Xie · University Of Texas Med Br Galveston$13,737,799
- Debra Burnin · Sri International$9,413,546
Research focus
Pharmacologic SubstancePreclinical DevelopmentFda ApprovedInnovationPharmaceutical PreparationsOralDrug KineticsEnvironmentFirst-In-HumanFormulationManufacturing ProcessAreaAnalytical MethodDrug Delivery SystemsAnimal ModelAcquired Immunodeficiency SyndromeAnimalsClinical TrialsDoseChemistryCytomegalovirus RetinitisDevicesDrug DevelopmentProduct Development
Grant awards (5)
IND-enabling Preclinical Development of a Sustained-release Pritelivir Intravaginal ring for the Treatment and Prophylaxis of Genital Herpes$1,000,000
R44 · FY2025 · AI
IND-enabling Preclinical Development of a Sustained-release Pritelivir Intravaginal ring for the Treatment and Prophylaxis of Genital Herpes$1,025,000
R44 · FY2024 · AI
IND-enabling Preclinical Development of a Sustained-release Pritelivir Intravaginal ring for the Treatment and Prophylaxis of Genital Herpes$1,025,000
R44 · FY2023 · AI
Long-acting injectable tacrolimus for chronic immunosuppression$1,023,600
R44 · FY2023 · AI
Long-acting injectable tacrolimus for chronic immunosuppression$1,024,014
R44 · FY2022 · AI